AstraZeneca's brain drain

When chief executive David Mott packs up his desk July 31 after 16 years at MedImmune he won't be alone.

Without the official AZ press release that accompanied Mott's announced departure on June 26, two other high-level executives have quietly left.

Jim Young, president of research and development, and Ed Mathers, executive vice president of corporate development and ventures, left in June. Young had worked at MedImmune for two decades and Mathers, six years.

Source